{
  "id": 7780104,
  "title": "NeOnc CEO purchases additional shares following trial results",
  "url": "https://urgent.news/2026/09/16/neonc-ceo-purchases-additional-shares-following-trial-results",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-16T12:04:32.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/neonc-ceo-purchases-additional-shares-following-trial-results-93CH-4903595"
  },
  "original_language": "en",
  "account": "NeOnc Technologies Holdings Inc. (NASDAQ:NTHI) disclosed on Monday that its CEO, Amir Heshmatpour, bought 35,000 shares of the company's common stock. The transaction, executed on the open market, amounted to roughly $115,400 at an average price of $3.30 per share, according to the company's press release. This purchase came after NeOnc's $15 million registered direct offering disclosed on September 9. Since announcing positive Phase 2a results for intranasal NEO100 on August 12, Heshmatpour has accumulated 111,000 shares, valued at approximately $418,700, at an average cost of $3.77 per share. The company's founder, chief medical officer, and chief scientific officer, Thomas C. Chen, also participated in the stock purchases, acquiring 49,016 shares, or about $210,000, within the same timeframe. Together, the two executives have collectively bought 160,016 shares, totaling approximately $629,000 in open-market transactions, as documented in Form 4 filings with the Securities and Exchange Commission. Heshmatpour further revealed that his most recent purchases have led to a total investment of over $1.5 million of his personal funds in NeOnc shares over the past year. The NEO100-01 Phase 2a study achieved its primary endpoint, demonstrating a six-month progression-free survival rate of 48.9% compared to the pre-specified 20% benchmark for standard care, with a median overall survival of 26.09 months. NeOnc is a clinical-stage biopharmaceutical company focusing on developing therapies for central nervous system cancers. The two executives' share purchases were made using personal funds and will be reported in subsequent SEC filings.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}